StreetInsider.com News Articles

Cantor Fitzgerald Starts Sol Gel Technologies Ltd. (SLGL) at Overweight

Wed, 14 Oct 2026 06:12:40 -0400

Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Sol Gel Technologies Ltd. (NASDAQ: SLGL) with a Overweight rating.

For an analyst ratings summary and ratings history on Sol Gel Technologies Ltd. click here. For more ratings news on Sol Gel Technologies Ltd. click here.

Shares of Sol Gel Technologies Ltd. closed at $68.30 yesterday.

Form 6-K Sol-Gel Technologies For: Oct 06

Tue, 06 Oct 2026 07:25:00 -0400

si-local-file:///var/storage/secattach/20261006/27151830.html

H.C. Wainwright Reiterates Buy Rating on Sol Gel Technologies Ltd. (SLGL)

Tue, 06 Oct 2026 06:59:01 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $110.00 price target on Sol Gel Technologies Ltd. (NASDAQ: SLGL).

The analyst commented: "SGT-610 pivotal top-line data readout rapidly approaching. We remind investors that SGT-610 (patidegib), which is being assessed in the orphan disease known as Gorlin syndrome, constitutes Sol-Gel's main value driver. SGT-610 is a topically applied hedgehog signaling pathway blocker formulated as a 2% gel. If approved, SGT-610 is expected to be the first product for the prevention of new basal cell carcinoma (BCC) lesions in Gorlin syndrome patients. Sol-Gel management anticipates release of top-line data from the pivotal

Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026

Wed, 30 Sep 2026 09:14:00 -0400

NESS ZIONA, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today announced it will host a KOL Investor Event on SGT-610 (patidegib gel, 2%) on Wednesday, October 14, 2026 in New York.

The event will feature Julie Breneiser, PA-C (Gorlin Syndrome Alliance), Ervin Epstein Jr., MD (Alta Bates Summit Medical Center), Kavita Sarin, MD, PhD (Stanford Cancer Institute), and Elizabeth M. Billingsley, MD, FAAD, FACMS, FASDS (Penn State College of Medicine), who will discuss the significant disease burden of Gorlin

Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026

Wed, 30 Sep 2026 09:14:00 -0400

Form 6-K Sol-Gel Technologies For: Sep 30

Wed, 30 Sep 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260930/27126202.html

Sol-Gel completes patient phase of SGT-610 Gorlin syndrome trial

Thu, 17 Sep 2026 08:30:58 -0400

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) announced that the last patient has completed the final scheduled study visit in its pivotal Phase 3 clinical trial evaluating SGT-610 (patidegib gel, 2%) for the prevention of basal cell carcinoma (BCC) lesions in adult patients with Gorlin syndrome.

The completion of the last patient last visit marks the end of the treatment and follow-up phase of the study. Sol-Gel said it is now proceeding with database lock and subsequent statistical analysis, with top-line results expected in late November 2026. The company, investigators, and patients remain blinded to treatment assignments.

The randomized, double-blind, vehicle-controlled trial enrolled 113

Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome

Thu, 17 Sep 2026 08:30:00 -0400

Last patient has completed the last scheduled study visit in the pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome
Top-line results remain on track for late November 2026

NESS ZIONA, Israel, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today announced that the last patient has completed the last scheduled study visit in the Company's pivotal Phase 3 clinical trial (SGT-610-01) evaluating SGT-610 (patidegib gel, 2%) for the prevention of BCC (basal cell carcinoma) lesions in

Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome

Thu, 17 Sep 2026 08:30:00 -0400

Last patient has completed the last scheduled study visit in the pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome
Top-line results remain on track for late November 2026

Form 6-K Sol-Gel Technologies For: Sep 17

Thu, 17 Sep 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260917/27073221.html

Form 4 Sol-Gel Technologies For: Sep 10 Filed by: Opaleye Management Inc.

Mon, 14 Sep 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260914/27059387.html

Form 6-K Sol-Gel Technologies For: Jun 30

Thu, 20 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260820/26953502.html

Form 6-K Sol-Gel Technologies For: Jun 30

Thu, 20 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260820/26953502.html

Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Thu, 20 Aug 2026 08:30:00 -0400

Pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout in late November 2026
Sol-Gel has initiated a proof-of-concept study in High-frequency BCC (HF-BCC)
Sol-Gel initiated a study evaluating topical patidegib as a neo-adjuvant in BCC surgery, prompted by physician interest in oral HHi use ahead of Mohs surgery
Sol-Gel has expanded its Gorlin syndrome pipeline with a provisional patent filing for an intra-cystic injectable targeting odontogenic keratocysts (OKC)

NESS ZIONA, Israel, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering

Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Thu, 20 Aug 2026 08:30:00 -0400

Pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout in late November 2026
Sol-Gel has initiated a proof-of-concept study in High-frequency BCC (HF-BCC)
Sol-Gel initiated a study evaluating topical patidegib as a neo-adjuvant in BCC surgery, prompted by physician interest in oral HHi use ahead of Mohs surgery
Sol-Gel has expanded its Gorlin syndrome pipeline with a provisional patent filing for an intra-cystic injectable targeting odontogenic keratocysts (OKC)

NESS ZIONA, Israel, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering

Form 4 Sol-Gel Technologies For: Aug 12 Filed by: Opaleye Management Inc.

Fri, 14 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260814/26930288.html

Form 4 Sol-Gel Technologies For: Aug 12 Filed by: Opaleye Management Inc.

Fri, 14 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260814/26930288.html

H.C. Wainwright Reiterates Buy Rating on Sol Gel Technologies Ltd. (SLGL)

Mon, 20 Jul 2026 06:52:00 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $110.00 price target on Sol Gel Technologies Ltd. (NASDAQ: SLGL).

The analyst commented: "We remind investors that SGT-610 (patidegib), which is being assessed in the orphan disease known as Gorlin syndrome, constitutes Sol-Gel's main value driver. SGT-610 is a topically applied hedgehog signaling pathway blocker formulated as a 2% gel. If approved, SGT-610 is expected to be the first product for the prevention of new basal cell carcinoma (BCC) lesions in Gorlin syndrome patients. Sol-Gel management anticipates release of top-line data from the pivotal Phase 3 trial of SGT-610 in Gorlin

Form 4 Sol-Gel Technologies For: Jul 13 Filed by: Opaleye Management Inc.

Wed, 15 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260715/26774133.html

Form 4 Sol-Gel Technologies For: Jul 13 Filed by: Opaleye Management Inc.

Wed, 15 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260715/26774133.html

Form 4 Sol-Gel Technologies For: Jul 08 Filed by: Opaleye Management Inc.

Fri, 10 Jul 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260710/26757782.html

Form 4 Sol-Gel Technologies For: Jul 08 Filed by: Opaleye Management Inc.

Fri, 10 Jul 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260710/26757782.html

Form 4 Sol-Gel Technologies For: Jul 01 Filed by: Opaleye Management Inc.

Thu, 02 Jul 2026 18:11:00 -0400

si-local-file:///var/storage/secattach/20260702/26729871.html

Form 4 Sol-Gel Technologies For: Jul 01 Filed by: Opaleye Management Inc.

Thu, 02 Jul 2026 18:11:00 -0400

si-local-file:///var/storage/secattach/20260702/26729871.html

Mizuho Starts Sol Gel Technologies Ltd. (SLGL) at Outperform

Wed, 24 Jun 2026 04:15:26 -0400

Mizuho analyst Uy Ear initiates coverage on Sol Gel Technologies Ltd. (NASDAQ: SLGL) with a Outperform rating and a price target of $285.00.

The analyst comments: “We initiate coverage of Sol-Gel Technologies (SLGL) with an Outperform rating and a $285 price target. We see Sol-Gel's SGT-610 (topical hedgehog inhibitor -- 2% patidegib), acquired from PellePharm, as a potential first-in-class FDA-approved therapy to prevent new basal cell carcinoma (BCC) lesions in Gorlin syndrome (GS), with ~$1B peak sales potential. First, we believe SGT-610 is relatively de-risked, given its validated mechanism of action as systemic hedgehog inhibitors (HHI) are already used off-label. Second,